181 related articles for article (PubMed ID: 36258093)
1. Risk of gastric and oesophageal adenocarcinoma following discontinuation of long-term proton-pump inhibitor therapy.
Holmberg D; Mattsson F; Xie S; Ness-Jensen E; El-Serag H; Lagergren J
J Gastroenterol; 2022 Dec; 57(12):942-951. PubMed ID: 36258093
[TBL] [Abstract][Full Text] [Related]
2. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.
Brusselaers N; Wahlin K; Engstrand L; Lagergren J
BMJ Open; 2017 Oct; 7(10):e017739. PubMed ID: 29084798
[TBL] [Abstract][Full Text] [Related]
3. Maintenance proton pump inhibition therapy and risk of oesophageal cancer.
Brusselaers N; Engstrand L; Lagergren J
Cancer Epidemiol; 2018 Apr; 53():172-177. PubMed ID: 29477057
[TBL] [Abstract][Full Text] [Related]
4. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study.
Masclee GM; Coloma PM; Spaander MC; Kuipers EJ; Sturkenboom MC
BMJ Open; 2015 Jan; 5(1):e006640. PubMed ID: 25633286
[TBL] [Abstract][Full Text] [Related]
5. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans.
Tan MC; El-Serag HB; Yu X; Thrift AP
Aliment Pharmacol Ther; 2018 Aug; 48(4):469-477. PubMed ID: 29956826
[TBL] [Abstract][Full Text] [Related]
6. Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer.
Brusselaers N; Lagergren J; Engstrand L
Cancer Epidemiol; 2019 Oct; 62():101585. PubMed ID: 31445426
[TBL] [Abstract][Full Text] [Related]
7. Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden.
Brusselaers N; Sadr-Azodi O; Engstrand L
J Gastroenterol; 2020 Apr; 55(4):453-461. PubMed ID: 31811561
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients.
Hvid-Jensen F; Pedersen L; Funch-Jensen P; Drewes AM
Aliment Pharmacol Ther; 2014 May; 39(9):984-91. PubMed ID: 24617286
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology and prevention of oesophageal adenocarcinoma.
Ness-Jensen E
Scand J Gastroenterol; 2022 Aug; 57(8):891-895. PubMed ID: 35234549
[TBL] [Abstract][Full Text] [Related]
10. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis.
Singh S; Garg SK; Singh PP; Iyer PG; El-Serag HB
Gut; 2014 Aug; 63(8):1229-37. PubMed ID: 24221456
[TBL] [Abstract][Full Text] [Related]
11. Proton pump inhibitors and risk of periampullary cancers--A nested case-control study.
Chien LN; Huang YJ; Shao YH; Chang CJ; Chuang MT; Chiou HY; Yen Y
Int J Cancer; 2016 Mar; 138(6):1401-9. PubMed ID: 26488896
[TBL] [Abstract][Full Text] [Related]
12. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK.
García Rodríguez LA; Lagergren J; Lindblad M
Gut; 2006 Nov; 55(11):1538-44. PubMed ID: 16785284
[TBL] [Abstract][Full Text] [Related]
13. Association between proton pump inhibitor use and risk of pneumonia in children: nationwide self-controlled case series study in Sweden.
Wang YH; Svanström H; Wintzell V; Ludvigsson JF; Pasternak B
BMJ Open; 2022 Apr; 12(4):e060771. PubMed ID: 35450917
[TBL] [Abstract][Full Text] [Related]
14. Risk of oesophageal adenocarcinoma in individuals with Barrett's oesophagus.
Holmberg D; Ness-Jensen E; Mattsson F; El-Serag HB; Lagergren J
Eur J Cancer; 2017 Apr; 75():41-46. PubMed ID: 28214656
[TBL] [Abstract][Full Text] [Related]
15. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study.
Poulsen AH; Christensen S; McLaughlin JK; Thomsen RW; Sørensen HT; Olsen JH; Friis S
Br J Cancer; 2009 May; 100(9):1503-7. PubMed ID: 19352380
[TBL] [Abstract][Full Text] [Related]
16. Risk of gastric cancer among long-term proton pump inhibitor users: a population-based cohort study.
Kim JW; Jung HK; Lee B; Shin CM; Gong EJ; Hong J; Youn YH; Lee KJ
Eur J Clin Pharmacol; 2023 Dec; 79(12):1699-1708. PubMed ID: 37861752
[TBL] [Abstract][Full Text] [Related]
17. Proton pump inhibitor discontinuation in long-term care.
Linsky A; Hermos JA; Lawler EV; Rudolph JL
J Am Geriatr Soc; 2011 Sep; 59(9):1658-64. PubMed ID: 21883102
[TBL] [Abstract][Full Text] [Related]
18. Gastro-oesophageal reflux symptoms and the risks of oesophageal cancer: are the effects modified by smoking, NSAIDs or acid suppressants?
Pandeya N; Webb PM; Sadeghi S; Green AC; Whiteman DC;
Gut; 2010 Jan; 59(1):31-8. PubMed ID: 19875392
[TBL] [Abstract][Full Text] [Related]
19. Use of proton pump inhibitors and the risk of cholangitis: a nationwide cohort study.
Min YW; Kang D; Shin JY; Kang M; Park JK; Lee KH; Lee JK; Lee KT; Rhee PL; Kim JJ; Guallar E; Cho J; Lee H
Aliment Pharmacol Ther; 2019 Oct; 50(7):760-768. PubMed ID: 31448440
[TBL] [Abstract][Full Text] [Related]
20. Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea.
Seo SI; Park CH; You SC; Kim JY; Lee KJ; Kim J; Kim Y; Yoo JJ; Seo WW; Lee HS; Shin WG
Gut; 2021 Nov; 70(11):2066-2075. PubMed ID: 33975868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
